Posted in | News

NanoViricides Submits Grant Application to DOD for Development of Broad-Spectrum Nanoviricides Drugs

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it has recently submitted a grant application to the Department of Defense. This grant, if awarded, will be used for the development of broad-spectrum nanoviricides drugs. If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure (MCM) against bio-terrorism and emerging infectious diseases such as Ebola/Marburg, and Dengue.

The Company has already demonstrated that some of the nanoviricides we have created are broad-spectrum. It is believed that viruses are unlikely to escape such broad-spectrum nanoviricides by mutation because such mutations would also cause a loss of infectivity.

At present, other MCM efforts have generally resulted in highly specific one-bug-one-drug type of therapies, such as vaccines, antibodies, certain anti-sense therapeutics, and some other antivirals. Thus, a large number of drugs, vaccines and antibodies would need to be stockpiled to mitigate the threat from a countless number of pathogens and their known mutants. Further, if a virus mutates further, then most such agents are likely to become ineffective. Mutations are common in many viruses, and can also be genetically engineered to produce devastating bio-terrorism agents.

The Company has assembled a strong team comprising several renowned Institutions and Companies for the proposed project. There is no guarantee that the grant application will result in any funding.

Ebola viruses cause devastating disease with mortality rates as high as 90%. Dengue has now become endemic in most of the tropical world, and is becoming an important public health threat in the United States. A second infection from an unrelated dengue virus subtype can be life-threatening, resulting in dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). There is currently no drug or vaccine available for dengue viruses. The worldwide market for a dengue treatment could be possibly in the billions of dollars.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 14). NanoViricides Submits Grant Application to DOD for Development of Broad-Spectrum Nanoviricides Drugs. AZoNano. Retrieved on April 14, 2024 from https://www.azonano.com/news.aspx?newsID=9677.

  • MLA

    NanoViricides, Inc. "NanoViricides Submits Grant Application to DOD for Development of Broad-Spectrum Nanoviricides Drugs". AZoNano. 14 April 2024. <https://www.azonano.com/news.aspx?newsID=9677>.

  • Chicago

    NanoViricides, Inc. "NanoViricides Submits Grant Application to DOD for Development of Broad-Spectrum Nanoviricides Drugs". AZoNano. https://www.azonano.com/news.aspx?newsID=9677. (accessed April 14, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides Submits Grant Application to DOD for Development of Broad-Spectrum Nanoviricides Drugs. AZoNano, viewed 14 April 2024, https://www.azonano.com/news.aspx?newsID=9677.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.